O.PE.R.A. BREAST - ONCOLOGY PROFESSIONAL REMOTE ACADEMY

1. 1.Sparano JA, et al.. TAILORx: freedom from recurrence from breast cancer at a distant site, 9-year rates. N Engl J Med. 2018
   Articolo scientificoN Engl J MedCerca su Google Scholar
2. 2.Kalinski K. RxPONDER Schema. NEJM. 2021
   RxPONDER Schema
   LibroCerca su Amazon
3. 3.Kalinski K. RxPONDER: outcomes in pre- and postmenopausal pts. NEJM. 2021
   RxPONDER: outcomes in pre- and postmenopausal pts
   LibroCerca su Amazon
4. 4.Kalinsky K.. Premenopausal patients <55yrs with low AMH do not derive benefit from CT. ASCO 2024. 2024
   Premenopausal patients <55yrs with low AMH do not derive benefit from CT
   LibroCerca su Amazon
5. 5.Buus et al.. Modules driving Recurrence Scores. J Clin Oncol. 2020
   Articolo scientificoJ Clin OncolCerca su Google Scholar
6. 6.Sparano JA, et al.. Within the same genomic-risk categories, clinical risk assessment identifies patients at different prognosis - TAILORx. NEJM. 2019
   Articolo scientificoNEJMCerca su Google Scholar
7. 7.Piccart et. al. Genomic test to inform on adjuvant treatments. Ann Oncol. 2021
   Articolo scientificoAnn OncolCerca su Google Scholar
8. 8.Bartlett JMS, et al.. Level IB evidence for BCI (H/I) (and MP) in predicting benefit from extended ET. Clin Cancer Res. 2022
   Articolo scientificoClin Cancer ResCerca su Google Scholar
9. 9.Griguolo G. et al.. POTENTIAL UTILITY OF GENOMIC TESTS TO GUIDE NAT IN HR+/HER2- BC BASED ON PERSONAL OPINION. Cancer Treat Rev. 2022
   Articolo scientificoCancer Treat RevCerca su Google Scholar

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).